NASDAQ:HRMY

Harmony Biosciences (HRMY) Stock Forecast, Price & News

$33.15

-1.21 (-3.52%)

(As of 12:09 PM ET)

Compare

Today's Range: $33.10
▼
$34.60
50-Day Range: $31.89
▼
$39.03
52-Week Range: $29.81
▼
$62.08

Volume: 119,340 shs
Average Volume: 675,605 shs
Market Capitalization: $1.99 billion

P/E Ratio: 10.14
Dividend Yield: N/A
Price Target: $60.78

Harmony Biosciences MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.70 Rating Score
Upside/Downside: 76.9% Upside
$60.78 Price Target
Short Interest: Bearish
21.64% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.56
Based on 15 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 33.75%
From $2.40 to $3.21 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.30 out of 5 stars

Medical Sector

7th out of 970 stocks

Pharmaceutical Preparations Industry

1st out of 456 stocks

4.4

Analyst's Opinion

Consensus Rating
Harmony Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 8 buy ratings, 1 hold rating, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $60.78, Harmony Biosciences has a forecasted upside of 76.9% from its current price of $34.36.
Amount of Analyst Coverage
Harmony Biosciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
21.64% of the float of Harmony Biosciences has been sold short.
Short Interest Ratio / Days to Cover
Harmony Biosciences has a short interest ratio ("days to cover") of 13.8, which indicates bearish sentiment.
Change versus previous month
Short interest in Harmony Biosciences has recently decreased by 5.04%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Harmony Biosciences does not currently pay a dividend.
Dividend Growth
Harmony Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for HRMY.

2.5

News and Social Media Coverage

News Sentiment
Harmony Biosciences has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 15 news articles for Harmony Biosciences this week, compared to 4 articles on an average week.
Search Interest
Only 4 people have searched for HRMY on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
7 people have added Harmony Biosciences to their MarketBeat watchlist in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Harmony Biosciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
28.40% of the stock of Harmony Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
86.23% of the stock of Harmony Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

4.4

Earnings and Valuation

Earnings Growth
Earnings for Harmony Biosciences are expected to grow by 33.75% in the coming year, from $2.40 to $3.21 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Harmony Biosciences is 10.51, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 114.42.
Price to Earnings Ratio vs. Sector
The P/E ratio of Harmony Biosciences is 10.51, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 98.39.
Price to Earnings Growth Ratio
Harmony Biosciences has a PEG Ratio of 0.49. PEG Ratios below 1 indicate that a company could be undervalued.
Price to Book Value per Share Ratio
Harmony Biosciences has a P/B Ratio of 5.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Harmony Biosciences (NASDAQ:HRMY) Stock

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. It offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

HRMY Price History

30 days | 90 days | 365 days | Advanced Chart

HRMY Stock News Headlines

September 27, 2023 | msn.com

Goldman Sachs Maintains Harmony Biosciences Holdings (HRMY) Sell Recommendation

September 26, 2023 | americanbankingnews.com

Harmony Biosciences (NASDAQ:HRMY) Downgraded to "Sell" at The Goldman Sachs Group

September 29, 2023 | PressReach (Ad)

Uranium Prices Surge as Nuclear Energy Becomes Key

Renewed interest in uranium and rising prices have created a favorable environment for new projects.

September 25, 2023 | msn.com

Goldman Sachs Downgrades Harmony Biosciences Holdings (HRMY)

September 25, 2023 | finance.yahoo.com

Short seller petitions FDA to reverse approval of Harmony Biosciences drug

September 25, 2023 | finance.yahoo.com

Nike downgraded amid US wholesale pressures, China risks: 4 big analyst cuts

September 24, 2023 | americanbankingnews.com

Needham & Company LLC Reiterates "Buy" Rating for Harmony Biosciences (NASDAQ:HRMY)

September 24, 2023 | americanbankingnews.com

Harmony Biosciences (NASDAQ:HRMY) Sees Strong Trading Volume

September 29, 2023 | PressReach (Ad)

Uranium Prices Surge as Nuclear Energy Becomes Key

Renewed interest in uranium and rising prices have created a favorable environment for new projects.

September 24, 2023 | seekingalpha.com

Harmony Biosciences: A Balancing Act As Investors Lose Some Sleep

September 20, 2023 | finance.yahoo.com

HARMONY BIOSCIENCES PRESIDENT & CEO JEFFREY M. DAYNO, M.D., NAMED TO 2023 PHARMAVOICE 100 LIST OF TOP INDUSTRY LEADERS

September 20, 2023 | americanbankingnews.com

Harmony Biosciences' (HRMY) Buy Rating Reaffirmed at Mizuho

September 15, 2023 | finance.yahoo.com

This Biotech Stock Pick Is Just Starting to Make Beautiful Music

September 13, 2023 | finance.yahoo.com

HARMONY BIOSCIENCES TO PARTICIPATE IN 2023 CANTOR GLOBAL HEALTHCARE CONFERENCE

September 9, 2023 | msn.com

Berenberg Initiates Coverage of Harmony Biosciences Holdings (HRMY) with Buy Recommendation

September 7, 2023 | markets.businessinsider.com

9 Analysts Have This to Say About Harmony Biosciences

September 7, 2023 | finance.yahoo.com

HARMONY BIOSCIENCES ANNOUNCES US FOOD & DRUG ADMINISTRATION ORPHAN DRUG DESIGNATION FOR PITOLISANT FOR TREATMENT OF IDIOPATHIC HYPERSOMNIA

September 7, 2023 | finance.yahoo.com

Harmony Biosciences Holdings Inc (HRMY): A Deep Dive into Its Performance Potential

September 6, 2023 | markets.businessinsider.com

Berenberg Bank Reaffirms Their Buy Rating on Harmony Biosciences Holdings (HRMY)

August 28, 2023 | seekingalpha.com

Harmony Biosciences gains as challenge to Wakix patent rejected

August 28, 2023 | bizjournals.com

Harmony Biosciences scores victory over activist short seller Scorpion with U.S. Patent Office decision on Wakix

August 28, 2023 | finance.yahoo.com

HARMONY BIOSCIENCES REITERATES CONFIDENCE IN WAKIX® (PITOLISANT) PATENTS FOLLOWING FAVORABLE DECISION BY U.S. PATENT AND TRADEMARK OFFICE (USPTO) TO DENY PETITION FOR REEXAMINATION

August 28, 2023 | markets.businessinsider.com

Will Harmony's INTUNE Trial Data Strike A Chord?

August 23, 2023 | msn.com

Cantor Fitzgerald Reiterates Harmony Biosciences Holdings (HRMY) Overweight Recommendation

August 22, 2023 | markets.businessinsider.com

Expert Ratings for Harmony Biosciences

August 14, 2023 | markets.businessinsider.com

Harmony Biosciences To Acquire Zynerba Pharma For Up To $200 Mln

August 14, 2023 | msn.com

Zynerba Pharma (NASDAQ:ZYNE) Skyrockets 3x On Acquisition By Harmony Bio (NASDAQ:HRMY)

See More Headlines

Receive HRMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harmony Biosciences and its competitors with MarketBeat's FREE daily newsletter.

HRMY Company Calendar

Last Earnings: 8/01/2023
Today: 9/29/2023
Next Earnings (Estimated): 11/07/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:HRMY
CUSIP: N/A
CIK: 1802665
Web: www.harmonybiosciences.com
Phone: 484-539-9800
Fax: N/A
Employees: 200
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $60.78
High Stock Price Forecast: $75.00
Low Stock Price Forecast: $43.00
Forecasted Upside/Downside: +76.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.70
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): $3.27
Trailing P/E Ratio: 10.51
Forward P/E Ratio: 14.32
P/E Growth: 0.49
Net Income: $181.47 million
Net Margins: 40.16%
Pretax Margin: 26.85%
Return on Equity: 42.49%
Return on Assets: 25.49%

Debt

Debt-to-Equity Ratio: 0.37
Current Ratio: 4.90
Quick Ratio: 4.84

Sales & Book Value

Annual Sales: $437.86 million
Price / Sales: 4.71
Cash Flow: $3.55 per share
Price / Cash Flow: 9.69
Book Value: $6.79 per share
Price / Book: 5.06

Miscellaneous

Outstanding Shares: 60,000,000
Free Float: 42,960,000
Market Cap: $2.06 billion
Optionable: Not Optionable
Beta: 0.43

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. Jeffrey S. Aronin (Age 55)
Founder & Non-Exec. Chairman
Comp: $19.6k

Dr. Jeffrey M. Dayno M.D. (Age 66)
Pres, CEO & Director
Comp: $762.15k

Mr. Sandip S. Kapadia CPA (Age 53)
M.B.A., Exec. VP & CFO
Comp: $962.6k

Mr. Jeffrey Dierks M.B.A. (Age 51)
Exec. VP & Chief Commercial Officer
Comp: $662.1k

Mr. Andrew Serafin J.D. (Age 48)
M.B.A., Exec. VP & Chief Strategy Officer
Comp: $605.42k

Mr. David Bradshaw
Head of Technical Operations

Luis Sanay
Head of Investor Relations

Mr. Christian Ulrich
Gen. Counsel & Corp. Sec.

Ms. Tricia Glover
Chief Compliance Officer

Ms. Audrey Murphy
Head of HR

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

HRMY Stock - Frequently Asked Questions

Should I buy or sell Harmony Biosciences stock right now?: 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harmony Biosciences in the last twelve months. There are currently 1 sell rating, 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HRMY shares.
View HRMY analyst ratings or view top-rated stocks.
What is Harmony Biosciences' stock price forecast for 2023?: 10 Wall Street analysts have issued 1-year target prices for Harmony Biosciences' stock. Their HRMY share price forecasts range from $43.00 to $75.00. On average, they anticipate the company's share price to reach $60.78 in the next year. This suggests a possible upside of 76.9% from the stock's current price.
View analysts price targets for HRMY or view top-rated stocks among Wall Street analysts.
How have HRMY shares performed in 2023?: Harmony Biosciences' stock was trading at $55.10 on January 1st, 2023. Since then, HRMY shares have decreased by 37.6% and is now trading at $34.36.
View the best growth stocks for 2023 here.
Are investors shorting Harmony Biosciences?: Harmony Biosciences saw a decline in short interest during the month of September. As of September 15th, there was short interest totaling 7,350,000 shares, a decline of 5.0% from the August 31st total of 7,740,000 shares. Based on an average daily volume of 532,100 shares, the days-to-cover ratio is currently 13.8 days. Approximately 21.6% of the shares of the company are short sold.
View Harmony Biosciences' Short Interest.
When is Harmony Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our HRMY earnings forecast.
How were Harmony Biosciences' earnings last quarter?: Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) announced its quarterly earnings results on Tuesday, August, 1st. The company reported $0.56 earnings per share for the quarter, missing the consensus estimate of $0.62 by $0.06. The company earned $134.22 million during the quarter, compared to analysts' expectations of $139.79 million. Harmony Biosciences had a net margin of 40.16% and a trailing twelve-month return on equity of 42.49%.
What ETFs hold Harmony Biosciences' stock?: ETFs with the largest weight of Harmony Biosciences (NASDAQ:HRMY) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), SPDR S&P Pharmaceuticals ETF (XPH), Virtus LifeSci Biotech Products ETF (BBP), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Invesco S&P SmallCap Health Care ETF (PSCH) and First Trust Nasdaq Pharmaceuticals ETF (FTXH).iShares U.S. Pharmaceuticals ETF (IHE).

What other stocks do shareholders of Harmony Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Harmony Biosciences investors own include Advance Auto Parts (AAP), Advanced Micro Devices (AMD), Boeing (BA), Berry Global Group (BERY), Bunge (BG), Carrier Global (CARR), Commercial Metals (CMC), Canadian Solar (CSIQ), Deere & Company (DE) and Eastman Chemical (EMN).
When did Harmony Biosciences IPO?: (HRMY) raised $101 million in an initial public offering (IPO) on Wednesday, August 19th 2020. The company issued 4,700,000 shares at $20.00-$23.00 per share. Goldman Sachs, Jefferies and Piper Sandler served as the underwriters for the IPO.
What is Harmony Biosciences' stock symbol?: Harmony Biosciences trades on the NASDAQ under the ticker symbol "HRMY."
How do I buy shares of Harmony Biosciences?: Shares of HRMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Harmony Biosciences' stock price today?: One share of HRMY stock can currently be purchased for approximately $34.36.
How much money does Harmony Biosciences make?: Harmony Biosciences (NASDAQ:HRMY) has a market capitalization of $2.06 billion and generates $437.86 million in revenue each year. The company earns $181.47 million in net income (profit) each year or $3.27 on an earnings per share basis.
How many employees does Harmony Biosciences have?: The company employs 200 workers across the globe.
How can I contact Harmony Biosciences?: Harmony Biosciences' mailing address is 630 W GERMANTOWN PIKE SUITE 215, PLYMOUTH MEETING PA, 19462. The official website for the company is www.harmonybiosciences.com. The company can be reached via phone at 484-539-9800 or via email at lcaperelli@harmonybiosciences.com.

This page (NASDAQ:HRMY) was last updated on 9/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial